Medicis Pharmaceutical Corporation

Other

James H Kulp

Michael T Nordsiek

Kodumudi S Balaji

Tze-Chiang Meng

Jason J Wu

Robert Babilon

Sharon F Levy

Valyn S Bahm

James H Lee

James Hurn-Joung Lee

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara&#xae; 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration ('FDA'), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration ('FDA') for Aldara&#xae; 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod

2&#xd7;2&#xd7;2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod

2&#xd7;2&#xd7;2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration ('FDA'), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration ('FDA') for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

Method of treating actinic keratosis with 3.75% imiquimod cream

2&#xd7;2&#xd7;2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod

An adjustable linear gauge including a linear track having uniformly spaced indentations along a surface thereof, and an adjustable member moveable along the track which includes a body portion carrying a stop member adapted to engage an end of a work piece to accurately position the work piece relative to a machine for performing an operation on the work piece. The adjustable member further includes a pivotable component that has a surface with one or more projections for engaging the spaced indentations on the track. The latter component is pivotally attached to the body portion and biased toward engagement with the indentations. The pivotable component further being is integral with a handle for manual application of a force to pivot the projections out of engagement with the indentations, the stop member and the surface with projections being located on rotationally opposite sides of the pivot point connecting the pivotable component to the body portion so that application of force against the end of the stop member causes an increase in pressure by the projections against the indentations. Preferably, the gauge further includes a graduated linear scale for visually indicating the position of the stop member. Also, the body portion includes an opening for viewing a point on said scale spaced on the body portion away from the stop member, and an adjustable moveable visual indicator for setting a point on the scale at a selected distance away from the stop member so that a linear distance subtraction can be factored into the positioning of the stop.

Adjustable linear gauge

Growing community of inventors

West Chester, PA, United States of America

James H Kulp